NCT02974647 - Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Lymphoma

Interventions

DRUG

Ruxolitinib

Trial Locations (10)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

RECRUITING

Memorial Sloan Kettering Commack, Commack

ACTIVE_NOT_RECRUITING

Northwestern Medicine (Data collection and specimen analysis), Chicago

ACTIVE_NOT_RECRUITING

University of Miami, Miami

ACTIVE_NOT_RECRUITING

Weill Cornell Medical College, New York

ACTIVE_NOT_RECRUITING

Dana Farber Cancer Institute, Boston

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown